When the tyrosine kinase inhibitor imatinib (Gleevec) was found to induce high remission rates in patients with chronic myeloid leukemia, this was hailed as a success for targeted tumor therapy. Since then, the repertoire of cancer types that respond to such inhibitors has expanded and researchers are beginning to grapple with the problem of acquired drug resistance. The activating kinase mutations targeted by these drugs can be viewed as the Achilles heel of cancer—they promote malignant progression, yet can turn cancer into a therapeutically exploitable disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl
Molecular Cancer Open Access 19 May 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hunter, T. & Eckhart, W. Cell 116, S35–S39, 1 p following S48 (2004).
Gschwind, A., Fischer, O.M. & Ullrich, A. Nat. Rev. Cancer 4, 361–370 (2004).
Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. Science 298, 1912–1934 (2002).
Rowley, J.D. Nature 243, 290–293 (1973).
Heisterkamp, N. et al. Nature 344, 251–253 (1990).
Kelliher, M.A., McLaughlin, J., Witte, O.N. & Rosenberg, N. Proc. Natl. Acad. Sci. USA 87, 6649–6653 (1990).
Daley, G.Q., Van Etten, R.A. & Baltimore, D. Science 247, 824–830 (1990).
Noble, M.E., Endicott, J.A. & Johnson, L.N. Science 303, 1800–1805 (2004).
Buchdunger, E. et al. Cancer Res. 56, 100–104 (1996).
Druker, B.J. et al. Nat. Med. 2, 561–566 (1996).
Druker, B.J. et al. N. Engl. J. Med. 344, 1031–1037 (2001).
Druker, B.J. et al. N. Engl. J. Med. 344, 1038–1042 (2001).
O'Brien, S.G. et al. N. Engl. J. Med. 348, 994–1004 (2003).
Buchdunger, E. et al. J. Pharmacol. Exp. Ther. 295, 139–145 (2000).
Buchdunger, E. et al. Proc. Natl. Acad. Sci. USA 92, 2558–2562 (1995).
Joensuu, H. et al. N. Engl. J. Med. 344, 1052–1056 (2001).
Heinrich, M.C. et al. J. Clin. Oncol. 21, 4342–4349 (2003).
Apperley, J.F. et al. N. Engl. J. Med. 347, 481–487 (2002).
Cools, J. et al. N. Engl. J. Med. 348, 1201–1214 (2003).
Rubin, B.P. et al. J. Clin. Oncol. 20, 3586–3591 (2002).
Gorre, M.E. et al. Science 293, 876–880 (2001).
Azam, M., Latek, R.R. & Daley, G.Q. Cell 112, 831–843 (2003).
Shah, N.P., Tran, C., Lee, F.Y., Chen, P., Norris, D. & Sawyers, C.L. Science 305, 399–401 (2004).
Demetri, G.D. et al. Proc. Am. Soc. Clin. Oncol. 23, 195 (2004).
Mendelsohn, J. & Baselga, J. J. Clin. Oncol. 21, 2787–2799 (2003).
Kaelin, W.G. Jr. Sci. STKE 2004, pe12 (2004).
Arteaga, C.L. & Baselga, J. Cancer Cell 5, 525–531 (2004).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baselga, J., Arribas, J. Treating cancer's kinase 'addiction'. Nat Med 10, 786–787 (2004). https://doi.org/10.1038/nm0804-786
Issue Date:
DOI: https://doi.org/10.1038/nm0804-786
This article is cited by
-
Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl
Molecular Cancer (2010)
-
Carcinogenesis, cancer therapy and chemoprevention
Cell Death & Differentiation (2005)